Chemclin

Beijing, China Founded: 2007 • Age: 19 yrs Acquired By Actis
In vitro diagnostic instruments and reagents are provided by Chemclin.
Annual revenue $58.9M Latest available
Total funding $312.5M 3 rounds
Employees - Tracked headcount
Investors 9 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Chemclin

Chemclin is a company based in Beijing (China) founded in 2007 was acquired by Actis in June 2013. Chemclin has raised $312.54 million across 3 funding rounds from investors including CICC, Actis and Orbimed.

  • Headquarter Beijing, China
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Medical Devices & Diagnostics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $58.86 M (USD)
    -2.35
    as on Dec 31, 2024
  • Net Profit
    $17.41 M (USD)
    -13.77
    as on Dec 31, 2024
  • EBITDA
    $22.7 M (USD)
    -10.04
    as on Dec 31, 2024
  • Total Equity Funding
    $312.54 M (USD)

    in 3 rounds

  • Latest Funding Round
    $292.04 M (USD), Series C

    Aug 13, 2018

  • Investors
    CICC

    & 8 more

  • Employee Count
    Not available
  • Acquired by
    Actis

    (Jun 01, 2013)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Chemclin

Chemclin has successfully raised a total of $312.54M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $292.04 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Chemclin

Chemclin has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include CICC, Actis and Orbimed.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity & venture capital firm
Locked Locked Locked
Corporate-backed venture capital firm focused on retail tech, mobile tech, and multiple sectors
Locked Locked Locked
VC firm that does investment in early stage companies in the US & China
Locked Locked Locked
Premium access

Investor details for Chemclin

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Chemclin

Investments
Premium access

Investment portfolio details for Chemclin

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Chemclin

Premium access

Detailed financials for Chemclin

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Chemclin Comparisons

Chemclin Primary company
Description
In vitro diagnostic instruments and reagents are provided by...
Location
Beijing, China
Founded Year
2007
Annual Revenue
$58.86 M (USD)
Net Profit
$17.41 M (USD)
EBITDA
$22.7 M (USD)
Employees
Not available
Premium access

Peer comparison for Chemclin

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Chemclin

Premium access

Detailed competitors of Chemclin

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Chemclin

Premium access

Complete news archive for Chemclin

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chemclin

Chemclin was founded in 2007.

Chemclin is headquartered in Beijing, China.

Chemclin is a funded company, having raised a total of $312.54M across 3 funding rounds to date.

Annual revenue of Chemclin is $58.86M as on Dec 31, 2024.

Chemclin, founded in 2007 as a subsidiary of China Diagnostics Medical Corporation, is based in Beijing, China. Diagnostic reagents and instruments for in vitro applications are developed, manufactured, and distributed by the company. Coverage includes chemiluminescence immunoassays, radioimmunoassay kits, and clinical chemistry assays. Systems and reagents address infectious diseases, tumor markers, liver fibrosis, diabetes, thyroid function, and fertility testing.

Chemclin has 9 investors. Key investors include CICC, Actis, Orbimed, WI Harper Group, and Free Trade Zone Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available